News | Women's Health | June 29, 2015

UCLA study finds partial breast irradiation produces similar results to whole breast irradiation, with treatment reduced to one week

UCLA, breast cancer, partial breast irradiation, Mitchell Kamrava

June 29, 2015 - Women diagnosed with breast cancer and treated with one week of partial breast radiation after surgical tumor removal saw no increase in cancer recurrence or difference in cosmetic outcomes, according to a new UCLA study. Subjects were compared to women who received radiation of the entire breast for a period of up to six weeks after surgery. The study is one of the largest ever done on partial breast irradiation.

The study lasted two decades and was led by Mitchell Kamrava, M.D., an assistant professor of radiation oncology at UCLA and member of the Jonsson Comprehensive Cancer Center. Kamrava and his team found that with partial breast irradiation, the total length of treatment can be reduced to a week because the smaller area of treatment allows for a higher dosage per treatment. Additionally, because partial breast radiation is more targeted, there is less exposure to vital organs like the lungs and the heart.

The new treatment, formally known as accelerated partial breast irradiation with interstitial multicatheter brachytherapy, works by radiating only breast tissue in and around the area where the tumor was removed. The current standard of care, called whole breast conservation therapy, involves irradiating the entire breast after surgery, usually over the course of five to seven weeks. This results in prolonged exposure to radiation and can potentially lead to more side effects.

"This gives us confidence there is a group of women who are suitable candidates for partial breast radiation and more women should discuss this treatment option with their doctors," said Kamrava.

The study followed more than 1,000 women who received partial breast irradiation after surgery, with an average follow-up of about seven years.

The next phase for Kamrava and his team will be to analyze the results of randomized trials comparing whole breast versus partial breast irradiation.

For more information: www.cancer.ucla.edu


Related Content

News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
News | Mammography

April 11, 2024 — Volpara Health Technologies Ltd., a global leader in software for the early detection and prevention of ...

Time April 11, 2024
arrow
News | Society of Breast Imaging (SBI)

April 11, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced today ...

Time April 11, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
Subscribe Now